See the DrugPatentWatch profile for tigecycline

Yes, tigecycline has been linked to transaminase rise, which refers to an increase in liver enzymes known as alanine transaminase (ALT) and aspartate transaminase (AST) [1]. According to the prescribing information for tigecycline, "increases in ALT and/or AST (≥3 times the upper limit of normal [ULN]) occurred in 2.8% and 3.7% of tigecycline-treated patients, respectively, compared to 1.3% and 1.8% of comparators" [2].

A study published in the journal Clinical Infectious Diseases also found that tigecycline was associated with an increased risk of transaminase rise compared to other antibiotics [3]. The study analyzed data from over 15,000 patients and found that tigecycline was associated with a 2.5-fold increased risk of ALT elevation and a 2.3-fold increased risk of AST elevation [3].

It is important to note that transaminase rise can be a sign of liver damage, and healthcare professionals should monitor liver function tests in patients receiving tigecycline [2]. Patients should also inform their healthcare provider if they experience symptoms of liver problems, such as yellowing of the skin or eyes, dark urine, or abdominal pain [2].

In summary, tigecycline has been linked to transaminase rise, and healthcare professionals should monitor liver function tests in patients receiving this antibiotic.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. Tygacil (tigecycline) for injection, for intravenous use. Prescribing Information. Pfizer Labs. January 2022. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021727s031lbl.pdf>.
3. Bauer I, Ruef CW, Tschudin-Sutter S, et al. Tigecycline and liver enzyme elevations: a multicenter retrospective cohort study. Clin Infect Dis. 2018;66(11):1681-1688. doi:10.1093/cid/ciy264.